C

Biographical Information

COMMITTEE MEMBERS

Dr. Robert Bergman received his Ph.D. at the University of Wisconsin in l966 under the direction of Jerome A. Berson. He spent 1966-1967 as a postdoctoral fellow in Ronald Breslow’s laboratories at Columbia, and following that joined the faculty of the California Institute of Technology. After ten years at Caltech he accepted a Professorship at the University of California, Berkeley, and a joint appointment at the Lawrence Berkeley National Laboratory; in 2002 he was appointed Gerald E.K. Branch Distinguished Professor at Berkeley. Among his honors are a Sloan Foundation Fellowship, a Dreyfus Foundation Teacher-Scholar Award, the American Chemical Society Award in Organometallic Chemistry, election to membership in the U.S. National Academy of Sciences and American Academy of Arts and Sciences, the U. S. Department of Energy E.O. Lawrence Award in Chemistry and the American Chemical Society Arthur C. Cope Award, and the Royal Society of Chemistry Sir Edward Frankland Prize Lectureship. Bergman has long been interested in exploratory and mechanistic studies in organic and organotransition metal chemistry. He is probably best known for his discovery of the thermal cyclization of cis-1,5-hexadiyne-3-enes to l,4-dehydrobenzene diradicals, a transformation that has been identified as a crucial DNA-cleaving reaction in several antibiotics that bind to nucleic acids, his discovery of the first soluble organometallic complexes that undergo intermolecular insertion of transition metals into the carbon-hydrogen bonds of alkanes, and his work on the synthesis and cycloaddition reactions of complexes with metal-



The National Academies | 500 Fifth St. N.W. | Washington, D.C. 20001
Copyright © National Academy of Sciences. All rights reserved.
Terms of Use and Privacy Statement



Below are the first 10 and last 10 pages of uncorrected machine-read text (when available) of this chapter, followed by the top 30 algorithmically extracted key phrases from the chapter as a whole.
Intended to provide our own search engines and external engines with highly rich, chapter-representative searchable text on the opening pages of each chapter. Because it is UNCORRECTED material, please consider the following text as a useful but insufficient proxy for the authoritative book pages.

Do not use for reproduction, copying, pasting, or reading; exclusively for search engines.

OCR for page 67
C Biographical Information COMMITTEE MEMBERS Dr. Robert Bergman received his Ph.D. at the University of Wisconsin in l966 under the direction of Jerome A. Berson. He spent 1966-1967 as a postdoctoral fellow in Ronald Breslow’s laboratories at Columbia, and following that joined the faculty of the California Institute of Technology. After ten years at Caltech he accepted a Professorship at the University of California, Berkeley, and a joint appointment at the Lawrence Berkeley National Laboratory; in 2002 he was appointed Gerald E.K. Branch Distin- guished Professor at Berkeley. Among his honors are a Sloan Foundation Fellowship, a Dreyfus Foundation Teacher-Scholar Award, the American Chemical Society Award in Organometallic Chemistry, election to mem- bership in the U.S. National Academy of Sciences and American Acad- emy of Arts and Sciences, the U. S. Department of Energy E.O. Lawrence Award in Chemistry and the American Chemical Society Arthur C. Cope Award, and the Royal Society of Chemistry Sir Edward Frankland Prize Lectureship. Bergman has long been interested in exploratory and mech- anistic studies in organic and organotransition metal chemistry. He is probably best known for his discovery of the thermal cyclization of cis- 1,5-hexadiyne-3-enes to l,4-dehydrobenzene diradicals, a transformation that has been identified as a crucial DNA-cleaving reaction in several antibiotics that bind to nucleic acids, his discovery of the first soluble organometallic complexes that undergo intermolecular insertion of tran - sition metals into the carbon-hydrogen bonds of alkanes, and his work on the synthesis and cycloaddition reactions of complexes with metal- 67

OCR for page 67
68 APPENDIX C heteroatom multiple bonds. His research has recently expanded to include application of carbon-hydrogen bond activation to problems in synthetic organic chemistry, nanovessel catalysis, and methods for the conversion of biomass to fuels and commodity chemicals. Dr. Joe Francisco is currently a William E. Moore Distinguished professor of Chemistry at Purdue University within the Departments of Chemistry and Earth and Atmospheric Sciences. Dr. Francisco received his B.S. from the University of Texas at Austin (1977), and his Ph.D. from the Massa - chusetts Institute of Technology (1983). Upon completion of his Ph.D., Dr. Francisco was a Postdoctoral Research Fellow at Cambridge University in England (1983-1985). He was also a Provost Postdoctoral Fellow at the Massachusetts Institute of Technolgy (1985). Dr. Francisco’s many achievements and recognitions include President of the National Organi - zation of Black Chemists and Chemical Engineers, 2006-2008; Alexandar von Humboldt Research Award for Senior U.S. Scientists, 2001; Fellow of the American Association for the Advancement of Science, 2001; Fel - low of the American Physical Society, 1998; Guggenheim Fellowship, 1993; Research Associate, California Institute of Technology, 1991; Dreyfus Teacher-Scholar, 1990-95; Alfred P. Sloan Research Fellow, 1990-1992; National Science Foundation Presidential Young Investigator, 1988-1993; Provost Postdoctoral Fellow, Massachusetts Institute of Technology, 1985. Dr. Charles T. Kresge is the Global R&D Director for Research and Engi- neering Sciences, Core Research & Development, of The Dow Chemi- cal Company. His career with Dow began in 1999 when Kresge joined Corporate R&D in Midland as Global R&D Director. Before joining Dow, Kresge was a senior member of the technical leadership for the Strate- gic Research Center, Mobil Technology Company, Mobil Corporation. He joined Mobil in 1979 as a research chemist in the Catalyst Synthesis & Development Group in Paulsboro, New Jersey. Kresge then went on to hold various research positions dealing with the discovery, develop - ment, and commercialization of catalytic materials and processes. In 1985, Kresge joined W. R. Grace & Company as Group Head, Fluid Catalytic Cracking Research. He returned to Mobil in 1987 to become head of the Exploratory Synthesis & Characterization Group at Mobil’s Paulsboro, New Jersey, Laboratory. In 1993, Kresge became head of Mobil’s activities for catalyst synthesis, characterization, and applications at Mobil’s Princ - eton and Paulsboro, New Jersey, Research Laboratories. This role was expanded in 1995 to include membranes, separations media, and inor- ganic materials science. Kresge became the technology leader and chief scientist for exploratory materials chemistry research at Mobil in 1997. In April 1999, Kresge joined Dow to assume his current position. Kresge

OCR for page 67
69 APPENDIX C is the corecipient of The Donald W. Breck Award in Molecular Sieve Sci - ence; recipient of an R&D 100 Award for Innovation and The Robert A. Welch Foundation Invited Lectureship in Nanochemistry; Chair, Gordon Research Conferences on Zeolitic and Layered Materials; Guest Editor, Current Chemistry: Current Opinion in Colloid and Interface Science; Editorial Board, Journal of Solid State Chemistry and Advanced Functional Materials; member of the Boards for the International Zeolite Association, Mesopo - rous Materials Association, and the International Congress on Catalysis; member, Council of the Gordon Research Conferences; member, Chemical Sciences Roundtable of the National Research Council; a member of the American Chemical Society, and a member of the University of California, Santa Barbara, Chemical Engineering Advisory Board. Kresge holds over 100 patents dealing with novel catalysts and their applications. He has presented over 50 invited talks and plenary lectures to the materials and catalysis communities and is the author of over 50 articles in scientific literature dealing with catalytic materials. Kresge is listed as one of the 100 most cited authors of the last ten years. His work was cited as one of the most important discoveries in chemistry in the last 75 years by the American Chemical Society. Kresge holds a bachelor’s degree in chemis- try from Swarthmore College and a doctorate in physical chemistry from the University of California, Santa Barbara. Dr. Douglas Ray is the Associate Laboratory Director for the Funda- mental & Computational Sciences Directorate at the Pacific Northwest National Laboratory (PNNL). Dr. Ray is responsible for PNNL’s research programs conducted for the Department of Energy’s Office of Science and for the National Institutes of Health. He directs more than 500 staff mem- bers in four research divisions: Atmospheric Sciences & Global Change, Biological Sciences, Chemical and Materials Science, and Computational Sciences & Mathematics. Dr. Ray joined PNNL in 1990. A laser spectrosco - pist, Dr. Ray’s research interests include the effects of weak intermolecular interactions on chemical phenomena in condensed phases, at interfaces, in clusters and in supramolecular complexes. He earned a B.S. degree in Physics from Kalamazoo College and a PhD in Chemistry at the Univer- sity of California at Berkeley. Dr. Ray is a member of the American Chemi- cal Society, American Physical Society, American Geophysical Union, and American Association for the Advancement of Science. SPEAKERS Dr. David Berry is a Partner at Flagship Ventures, where he focuses on investing in and founding early-stage life science and sustainability ven - tures. He is a founder of Flagship portfolio companies LS9, Joule Unlim -

OCR for page 67
70 APPENDIX C ited, Theracrine, Eleven Biotherapeutics, Essentient, among others. David currently serves as founding CEO at Essentient, and previously served as founding CEO of Joule and Theracrine. David received a PhD from MIT and an MD from Harvard. Dr. Robert (Bob) Lees, Ph.D., is a program director in the Division of Pharmacology, Physiology, and Biological Chemistry at the National Insti- tute of General Medical Sciences, where he manages grants in synthetic organic chemistry. Prior to joining the National Institute of General Medi- cal Sciences (NIGMS), he was a program director in the Developmental Therapeutics Program in the Division of Cancer Treatment and Diagnosis at the National Cancer Institute. Lees earned a B.S. in chemistry from Duke University and a Ph.D. in organic chemistry from Stanford Univer- sity. He conducted postdoctoral research at the Massachusetts Institute of Technology. Patty McAllister serves as Vice President of Government Relations and External Affairs at the Council of Graduate Schools in Washington, DC. She represents the interests of graduate education with federal policy makers, opinion leaders and other stakeholders. She is an experienced executive, having previously served as Executive Director of Public Affairs in the Communications and Public Affairs Division of Educational Testing Service (ETS), where she was responsible for directing a corporate-wide initiative on teacher quality. Previously at ETS, she served as Executive Director of State and Federal Relations for eight years. Ms. McAllister is a contributing author of The Path Forward: The Future of Graduate Education in the United States (2010). She has provided overall direction for the pro- duction of numerous reports including Broadening Participation in Graduate Education (2009); Graduate Education and the Public Good (2008); Graduate Education: The Backbone of American Competitiveness and Innovation (2007); Where We Stand on Teacher Quality (2004); and the No Child Left Behind Act: A Special Report (2002). She holds a BA in political science and a master’s degree in Public Administration (MPA). Dr. Matthew Platz is the Division Director for the National Science Foun- dation Division of Chemistry. Dr. Platz was born in Bronx, New York and obtained B.Sc. degrees in chemistry and mathematics from the State Uni- versity of New York at Albany in 1973, and a Ph.D. in chemistry from Yale University in 1977. Following a post doctoral year at the University of Chicago, he joined the faculty of The Ohio State University as an Assistant Professor of Chemistry in 1978. Dr. Platz was promoted to Associate Pro - fessor in 1984, to full Professor in 1990 and served as Department Chair from 1994-1999. He has won university awards for distinguished teaching

OCR for page 67
71 APPENDIX C and research and in 2001 he was named Distinguished University Profes- sor of Chemistry. Dr. Platz maintains an active research laboratory, which is funded by the National Science Foundation and the National Institutes of Health. A common theme is the use of photochemical techniques to generate and study highly reactive intermediates such as carbenes and nitrenes. His research has been recognized by the Cope Scholar award of the American Chemical Society and the Remsen Award. Dr. Gary Schuster is currently the Vasser Woolley Professor within the Department of Chemistry and Biochemistry at the Georgia Institute of Technology. Dr. Schuster received his B.S. from Clarkson College of Tech- nology (1968), and his Ph.D. from the University of Rochester (1971). Dr. Schuster was the recipient of the Chancellor’s Award, University System of Georgia–1998; the American Chemical Society A C. Cope Scholar Award, Paul Flory-IBM Fellowship, and the ACS Herty Medal. Dr. Schuster’s research interests include oxidative damage to DNA. The loss of an electron (oxidation) of duplex DNA results in the formation of a nucleobase radical cation (electron “hole”) that is subsequently con- sumed in chemical reactions that often lead to mutations. We have found that nucleobase damage need not occur at the site of the initial oxidation. Radical cations in DNA can migrate long distances (hundreds of Å) by a reversible hopping process before being trapped irreversibly by reaction with H2O and O2. A defining characteristic of this process is the preferen- tial reaction at guanine. We showed that the reactions of nucleobase radi- cal cations in DNA are determined by the specific sequence of bases that comprise the oligonucleotides. In particular, Dr. Schuster’s team observes that under certain circumstances oxidative reactions occurs at thymines despite the fact that it has a high oxidation potential. The consequences and mechanism of this reaction are under active investigation. Dr. Bassam Shakhashiri is the first holder of the William T. Evjue Distin- guished Chair for the Wisconsin Idea at UW-Madison. He is well known internationally for his effective leadership in promoting excellence in sci - ence education at all levels, and for his development and use of demon- strations in the teaching of chemistry in classrooms as well as in less for- mal settings, such as museums, convention centers, shopping malls, and retirement homes. The Encyclopedia Britannica sites him as the “dean of lecture demonstrators in America.” His scholarly publications, including the multi-volume series, Chemical Demonstrations: A Handbook for Teachers of Chemistry, are models of learning and instruction that have been trans- lated into several languages. He is an advocate for policies to advance knowledge and to use science and technology to serve society. He pro - motes the exploration and establishment of links between science, the arts

OCR for page 67
72 APPENDIX C and the humanities, and the elevation of discourse on significant societal issues related to science, religion, politics, the economy, and ethics. Profes- sor Shakhashiri is the 2011 President-Elect of the American Chemical Soci- ety, and will serve one-year terms as president in 2012 and immediate past president in 2013. He completed undergraduate work at Boston Univer- sity (Class of ‘60) with an A. B. degree in chemistry, served as a teaching fellow at Bowdoin College for one academic year and then earned M.Sc. and Ph.D. degrees in chemistry at the University of Maryland (1964 and 1968, respectively). After a year of postdoctoral research and two years as a junior member of the chemistry faculty at the University of Illinois- Urbana, Professor Shakhashiri joined the faculty of the UW-Madison in 1970, a position he still holds. In 1977 he became the founding chair of the UW System Undergraduate Teaching Improvement Council, now called the Office of Professional and Instructional Development. In 1983 he founded the Institute for Chemical Education (ICE) and served as its first director. His work with ICE inspired the establishment of the Center for Biology Education, the Merck Institute for Science Education, the Miami University (of Ohio) Center for Chemical Education, the Sacred Heart University SMART Center, and others. In 2002 he founded the Wisconsin Initiative for Science Literacy (WISL) and continues to serve as its director. From 1984 to 1990 Professor Shakhashiri served as Assistant Director of the National Science Foundation (NSF) for Science and Engineering Edu - cation. As the NSF chief education officer he presided over the rebuilding of all the NSF efforts in science and engineering education after they had been essentially eliminated in the early 1980s. His leadership and effec - tiveness in developing and implementing national programs in science and engineering education have helped set the annual NSF education budget at its current level of over $900 million. His NSF strategic plan launched the systemic initiatives and most of the other NSF education programs of the last two decades. Professor Shakhashiri is an elected fel - low of the South Carolina Academy of Science, the Alabama Academy of Science, the New York Academy of Science, and the Wisconsin Academy of Sciences, Arts and Letters. He is the recipient of honorary doctoral degrees from George Washington University, Illinois State University, Ripon College, University of Colorado, Grand Valley State University, University of South Carolina and Lebanese American University. He is a national and international consultant to government agencies, academic institutions, industry, and private foundations on policy and practice mat- ters related to science and to education at all levels. Professor Shakhashiri and his wife June live in Madison. Dr. George M. Whitesides was born August 3, 1939 in Louisville, KY. He received an A.B. degree from Harvard University in 1960 and a Ph.D. from

OCR for page 67
73 APPENDIX C the California Institute of Technology (with J.D. Roberts) in 1964. He was a member of the faculty of the Massachusetts Institute of Technology from 1963 to 1982. He joined the Department of Chemistry of Harvard Univer- sity in 1982, and was Department Chairman 1986-1989, and Mallinckrodt Professor of Chemistry from 1982-2004. He is now the Woodford L. and Ann A. Flowers University Professor. PANEL MEMBERS Dr. Julie Aaron joined the DSU faculty in 2010, and teaches biochem- istry and general chemistry. She received her undergraduate degree in Chemistry from McMaster University and her Ph.D. in Chemistry from the University of Pennsylvania. Her dissertation focused on the structure and function of the metalloenzymes human carbonic anhydrase and epi- isozizane synthase from Streptomyces coelicolor. Her research interests include metalloenzymes, protein X-ray crystallography, and evolutionary relationships among proteins. Dr. Aaron lives in Bucks County, where she enjoys baking, reading, gardening, and generally being outdoors. She is an avid Phillies fan, loves to travel, and is an aspiring cyclist. Dr. Bill Beaulieu is currently the Manager of Polyolefin Catalyst and Product Development at Chevron Phillips Chemical Company LLC. Dr. Beaulieu is the senior executive and part of the R&T leadership team with technical expertise, operational know-how, and business acumen. His industry background spans chemicals, plastics, petroleum, manu- facturing, engineering, and technology with Chevron Phillips Chemical Company and Phillips Petroleum. Dr. Beaulieu has significant experience managing the development of new products, creating new market oppor- tunities, increasing sales, and generating profits. Dr. Beaulieu is currently responsible for the discovery, development, and commercialization of new proprietary catalyst systems for olefin polymerizations including ethylene, propylene, and other alpha olefins. In addition, he is responsible for development of research programs and strategies which lead to new products and their timely commercialization. Dr. Thomas Degnan, manager of Breakthrough and New Leads Technol- ogy at ExxonMobil Research and Engineering Co. received his doctoral degree in chemical engineering from the University of Delaware in 1977. He and six members of his team won the recognition of “Hero of Chem - istry” by the American Chemical Society for developing a novel, cost- effective and environmentally friendly polyester production catalyst and process. Dr. Degnan went to graduate school at UD after receiving his bachelor’s degree in chemical engineering from the University of Notre

OCR for page 67
74 APPENDIX C Dame in 1973. He also earned a master’s degree in business administra- tion from the University of Minnesota in 1980. Dr. Degnan joined 3M’s Central Research Division in 1976 and then moved to Mobil’s Central Research Laboratory (CRL) in Princeton, N.J., in 1980. In 1989 he transferred to Mobil’s Paulsboro Research Labora - tory as group leader for hydroprocessing catalyst development. He was promoted to scientist in 1993, and, later the same year, he was appointed as manager of the Catalyst Technology Group in Mobil’s Research, Engi - neering and Environmental Affairs organization. In February 2000, Dr. Degnan was appointed laboratory director in ExxonMobil’s Research and Engineering’s Corporate Strategic Research Laboratory in Annandale, N.J., and in August 2004 he was appointed catalyst technology director for the Process Research Laboratories in ExxonMobil Refining and Sup- ply Company. He was promoted to his present position in August 2006. Degnan is a member of the Catalyst Club of New York and the North American Catalyst Society and is vice-chairman of the Research & Devel - opment Council of New Jersey. He also is a member of the advisory coun- cil of UD’s Center for Catalytic Science and Technology, the Engineering Advisory Council at the University of Notre Dame, the New Directions Council of Purdue University’s Chemical Engineering Department and the advisory council for the Department of Chemical and Biomolecular Engineering at Johns Hopkins University. Dr. Degnan is the named inven- tor or coinventor on approximately 100 U.S. patents and has authored or coauthored more than 35 articles and outside presentations including one book and one monograph. Dr. Rajiv Dhawan was born in Vancouver, British Columbia, Canada in 1975 and received his Bachelor of Science degree from Simon Fraser Uni - versity in Burnaby, British Columbia. He received his Ph.D. from McGill University in Montreal, Quebec in 2004 in the area of metal catalyzed multicomponent coupling chemistry with Professor Bruce Arndtsen. This was followed by a postdoctoral appointment at Stanford University, with Professor Barry M. Trost as an NSERC (National Science and Engineering Research Council of Canada) Postdoctoral Fellow, where he worked on method development and on the total synthesis of a natural product. Dr. Dhawan started his career at DuPont Central Research & Development as a Research Chemist and worked on a range of programs including devel - opment of high strength fibers and new routes for pesticide intermediates. In October 2011, he was promoted to DuPont Science & Technology Talent Acquisition Manager. Dr. Michael Doyle received his B.S. in Chemistry from the College of St. Thomas; his Ph.D. in Organic Chemistry from Iowa State University;

OCR for page 67
75 APPENDIX C and completed a Postdoctoral at the University of Illinois, Chicago. Dr. Doyle is currently Professor and Chair of the University of Maryland’s Department of Chemistry and Biochemistry. Dr. Doyle’s research inter- ests include asymmetric catalysis with metal carbenes and Lewis acids; structural design and chemistry of dirhodium carboxamidates; catalytic chemical oxidations; bioinorganic chemistry of nitrogen oxides and nitro- syls; reductions by organosilanes. Dr. Doyle belongs to a number of pro - fessional organizations, including the American Chemical Society (ACS), Fellow; American Association for the Advancement of Science (AAAS), Fellow; Royal Society of Chemistry, Fellow. Dr. Doyle has received many recognitions and honors, including NOBCChE Presidential Award for Outstanding Partner in Academia (2011); Fellow, American Chemical Society (2009); Edward Leete Award (2007), ACS Division of Organic Chemistry; Arthur C. Cope Senior Scholar Award (2006) from the Ameri- can Chemical Society; Outstanding Chemistry Alumni Award, Iowa State University (2006); Harry and Carol Moser Award (2005), Santa Clara Val- ley Section of the ACS; Merit Award, National Institutes of Health (2003); ACS George C. Pimentel Award in Chemical Education (2002); Gilman Research Award (2001) from Iowa State University; Paul G. Gassman Distinguished Service Award (1998), ACS Division of Organic Chemistry; Japan Society for the Promotion of Science (JSPS) Invitation Fellowship (1996); James Flack Norris Award for Outstanding Achievements in the Teaching of Chemistry (1995), Northeastern Section of the ACS; Alexander von Humboldt Senior Research Award for U.S. Scientists (1995); Elected Fellow of AAAS (1995); D.Sc. Honoris Causa of the Russian Academy of Sciences (1994); ACS Award for Research at Undergraduate Institu- tions (1988); Chemical Manufacturers Association Catalyst Award (1982); Camille & Henry Dreyfus Foundation Teacher-Scholar Award (1973). To date, Dr. Doyle has mentored 145 undergraduate students who are coau- thors of research publications, 60 of whom have received their Ph.D. in the chemical sciences; 45 Postdoctoral Associates; 6 students who received Ph.D. degrees and 2 students who received M.S. degrees (only since 2003). Dr. Marye Anne Fox, a world-renowned chemist, is the seventh chancel- lor of the University of California, San Diego and distinguished profes- sor of chemistry. Since her appointment as chancellor of UC San Diego, the university has established new research and partnership ventures to further innovation and increase international collaboration, achieved an ambitious $1 billion campaign goal, expanded academic and campus programs and facilities, received national and international recognition in prominent university rankings and assembled a strong, diverse leader- ship team to ensure the university’s continued rise in excellence. Before her current appointment, Dr. Fox served as North Carolina State Univer-

OCR for page 67
76 APPENDIX C sity’s 12th chancellor, as distinguished university professor of chemistry at NC State (from 1998 to 2004) and as Waggoner Regents Chair in chem- istry and Vice President for Research at the University of Texas at Austin. She joined the faculty of the University of Texas at Austin in 1976, after a postdoctoral appointment at the University of Maryland. Dr. Fox received her B.S. from Notre Dame College and her Ph.D. from Dartmouth College, both in chemistry. She has been elected to membership in the National Academy of Sciences and the American Philosophical Society, and to fellowships both in the American Academy of Arts and Sciences and the American Association of Advancement of Science. In October 2010, President Barack Obama named Dr. Fox to receive the National Medal of Science, the highest honor bestowed by the United States government on scientists, engineers and inventors. She has also received honorary degrees from 12 institutions in the U.S. and abroad. She was born in Can- ton, Ohio in 1947. Dr. Heather A. Gennadios is a Chemist in the Division of Manufactur- ing Technologies at the Center for Veterinary Medicine, Food and Drug Administration. Her educational background includes a Bachelor of Sci - ence in Biochemistry from the University of North Carolina at Chapel Hill (1999) and a PhD in Biological Chemistry from the University of Pennsylvania (2008). Prior to her PhD, she also worked as an analytical chemist in the pharmaceutical industry for 3 years. Her current work focuses on the review of biotherapeutic drugs, including such technolo- gies as recombinant proteins and stem cells. She has recently participated in writing a Guidance for Industry (GFI) document and is the leader for several technology teams as part of CVM’s Innovation Initiative. She has also helped design and currently teaches a course for FDA investigators on Biological Therapeutics Manufacturing. Dr. Paul L. Houston is Dean of the College of Sciences and Professor of Chemistry and Biochemistry at The Georgia Institute of Technology. He started his professorial career at Cornell University in 1975 following undergraduate study at Yale, doctoral work at MIT, and postdoctoral research at the University of California at Berkeley. He was formerly Chair of the Cornell Department of Chemistry and Chemical Biology (1997-2001), Senior Associate Dean of the College of Arts and Sciences (2002-2005), and the Peter J. W. Debye Professor of Chemistry. He was a member of the Cornell Center for Materials Research, the Kavli Institute at Cornell University for Nanoscale Science, and the Graduate Field of Applied Physics. Dr. Houston has been an Alfred P. Sloan Research Fel- low (1979-1981), a Camille and Henry Dreyfus Teacher Scholar (1980), and a John Simon Guggenheim Fellow (1986-1987). He served as a Senior

OCR for page 67
77 APPENDIX C Editor of the Journal of Physical Chemistry (1991-1997), as Chair of the American Physical Society Division of Laser Chemistry (1997-98), and as a member of the Science and Technology Steering Committee of Brookhaven National Laboratories (1998-2005). In 2001 he shared with David W. Chandler the Herbert P. Broida Prize of the American Physi- cal Society for work on product imaging in chemical dynamics. He was elected a fellow of the American Academy of Arts and Sciences in 2005. Dr. David Kronenthal is currently Vice President of Early Phase Chemical Development at Bristol-Myers Squibb. David Kronenthal attended Lehigh University and graduated in 1974 with a B.A. in Natural Sciences. He did his graduate work at the University of Connecticut studying Beckmann Fragmentation reactions and received a Ph.D. in 1978. From 1978-1980, Dave conducted postdoctoral research at Columbia University in the laboratories of Professor Gilbert Stork where he worked on the synthesis of histrionicotoxin. In 1980, Dave joined E.R. Squibb in the Department of Drug Discovery where he conducted research in the area of monocy- clic, b-lactam antibiotics. In 1985, he moved to the department of Process Research and Development where he has spent the last 27 years identify - ing and developing synthetic routes to drug candidates including several commercial products. Dr. Kronenthal is currently Vice President, Early Phase Chemical Development. He is responsible for a department of 95 scientists at the BMS New Brunswick site comprising Chemistry Devel - opment from preclinical through Phase II as well as the Catalysis, Bioca - talysis, Separations/Enabling Technologies, and Outsourcing functions. He has been cochair of the Bristol-Myers Squibb Unrestricted Chemistry Grant Committee since 2003. Dr. Joydeep Lahiri is currently the Division Vice President and Senior Research Director of Organic and Biochemical Technologies at Corning, Inc. Dr. Lahiri and his group’s research efforts at Corning are looking for new ways to provide better, more comprehensive drug screening information; identify and eliminate failures early in the drug discovery process; overcome previous technological limitations; and streamline the process of drug discovery. Dr. Lahiri leverages Corning’s broad exper- tise to develop more efficient, accurate ways to capture valuable bio- information early in the research process. He is also focusing on ways to eliminate extra steps in the research process such as end-user DNA labeling, which will not only save time but will minimize the chances of human error—two valuable advancements in drug discovery research. Dr. Lahiri’s accomplishments, and those of his colleagues, have been cited in key industry journals, including Chemical and Engineering News, Nature-Science Online, BioArray News, Analytical Chemistry, and Nature Biotechnology.

OCR for page 67
78 APPENDIX C Dr. Sander Mills is a vice president in discovery and preclinical sciences, and global head of chemistry. His areas of responsibility include discovery chemistry, process chemistry, analytical chemistry, structural chemistry, and chemistry modeling and informatics. After graduating from Drew University, he completed his Ph.D. in organic chemistry in Professor Peter Beak’s laboratory at the University of Illinois at Urbana/Champaign. He then carried out postdoctoral studies in the laboratories of Professor Clayton H. Heathcock at the University of California, Berkeley as an NIH postdoctoral fellow. Dr. Mills joined Merck Research Laboratories in 1985 in the department of process research, and moved to the medicinal chem- istry area in 1989. Dr. Mills’ research at Merck has been wide-ranging, dealing with the design and synthesis of small molecules to treat asthma, pain, HIV infection, autoimmune diseases, and CNS disorders. In 1993 he was part of the team that discovered aprepitant (EMEND®), which in 2003 became the first substance P antagonist marketed for the prevention of chemotherapy-induced nausea and vomiting. He and his group went on to identify fosaprepitant (IVEMEND®), a water-soluble prodrug of apre- pitant for parenteral administration, which gained regulatory approval in 2008. Dr. Mills has been an author or coauthor on more than 90 papers in professional journals on drug design, synthetic organic chemistry and the biology of medicinally active substances. He has been an inventor or coinventor on eighty U.S. patents covering an array of drug candidates and synthetic methods. He is a member of the Organic Chemistry and Medicinal Chemistry Sections of the American Chemical Society, AAAS and Sigma Xi. Dr. Jennifer Schomaker is an Assistant Professor within the Chemistry Department at The University of Wisconsin. Research in the Schomaker group is driven by the need for more efficient methods to transform simple hydrocarbons into more complex building blocks for synthesis. Our program will encompass new catalyst development and optimiza- tion, elucidation of reaction mechanisms and applications of new meth - odologies to the synthesis of natural products and other useful molecules. Particular emphasis will be placed on the design of catalysts that can utilize inexpensive greenhouse gases for useful organic transformations. The potential applications of our new catalysts to industrially impor- tant transformations will also be explored. Projects in our group are designed to offer students the ability to gain skills that will serve them well throughout their scientific careers, whether in an academic, govern - ment or industrial setting. These include standard techniques for the synthesis of organic and organometallic compounds, the handling and manipulation of air-sensitive materials, mechanistic and kinetic studies,

OCR for page 67
79 APPENDIX C advanced NMR techniques, basic computational chemistry, total synthesis and training in scientific writing and presentation skills. Dr. Siddhartha Shenoy is a Senior Research Chemist at DuPont Central Research and Development. He received his B.S. in Chemistry from the University of Virginia in 2001. He then moved to California to work on his Ph.D. under the direction of Professor Keith Woerpel at the University of California, Irvine. Dr. Shenoy’s graduate work was focused in the areas of synthetic methodology development and physical organic chemistry, namely in the mechanistic study of chemo-, regio-, and stereoselectivity in the reactions of heteroatom-stabilized carbocations. Upon completion of his Ph.D. in 2006, Dr. Shenoy joined the laboratory of Professor Julius Rebek as a Skaggs Postdoctoral Associate at The Scripps Research Insti - tute in La Jolla, California. During his time in the Rebek group, Dr. Shenoy developed a novel organocatalytic system that mimicked the function of terpene cyclase enzymes. Dr. Shenoy joined DuPont Central Research and Development in 2008. Dr. David Tellers received his Ph.D. in Chemistry from Professor Robert G. Bergman at U.C. Berkeley in 2001 and subsequently joined Merck where he has had the opportunity to support programs across the phar- maceutical development paradigm, from initial discovery to commercial launch. He started at Merck in the Chemical Engineering Department and focused on the optimization of organic reactions through kinetic analysis. He then transitioned to Process Research where he assisted in the creation of a chemocatalysis group and worked on synthetic route development for clinical candidates. He is currently a Senior Research Fellow in the Department of Medicinal Chemistry where he is working on the develop- ment of oligonucleotide therapeutics. Dr. Samuel Thomas is currently an Assistant Professor of Chemistry at Tufts University. He received his B.S. (2000) from the University of Roch - ester, and his PhD (2006) from MIT. Dr. Thomas was an American Cancer Society Postdoctoral Fellow (Harvard University) from 2006-2009. The Thomas lab takes an interdisciplinary approach to design and synthesis of organic materials. They combine synthesis, physical organic chemistry, photophysics, and electrostatics. Research includes (1) Electrostatically responsive materials that undergo a change in properties upon exposure to a stimulus such as changing the sign of charge upon contact electrifi- cation. Since a consistent theory that predicts how a material will charge upon contact with another material does not exist, they are developing rules to guide the design of materials for next-generation antistatic mate - rials, label-free chemical detection, and chemically- or photochemically-

OCR for page 67
80 APPENDIX C triggered electrostatic actuators. (2) Development of conjugated materials that are highly amplifying optical sensing materials where mobile excited states can transfer their energy (or be quenched) by electron, hole, or energy acceptors throughout the polymer backbone. The output for sens- ing applications of these materials is either fluorescence quenching or energy transfer, both of which have large background signal. The Thomas group is designing “materials amplification” from mobile excitons with dark-field sensing by using small amounts of reactive quenching traps and prequenched materials that radiate by coupling to plasmons upon binding. (3) Development of multifunctional polymers that bear ligands that bind specifically to targeted surfaces and thus serve as inhibitors with larger binding constants than their monomeric counterparts. Their research focuses on polymers that combine ligands for binding selectively to a surface with other useful functions and also take advantage of recent developments in controlled polymerization techniques to exert greater control over the distribution of functional moieties. Applications of such materials includes singlet oxygen photosensitizers for photodynamic therapy and thermally responsive materials for selective precipitation. Dr. Holden Thorp has been an undergraduate student, a chemistry pro- fessor, a planetarium director, an inventor and entrepreneur, as well as a dean, at Carolina. He graduated with honors, won teaching awards, chaired a powerhouse chemistry department, developed technology for electronic DNA chips, founded spin-off companies, and succeeded as an administrator. As the 10th chancellor, Dr. Thorp draws from those experi - ences in leading Carolina, one of the world’s great research universities. A North Carolina native, Dr. Thorp grew up in Fayetteville in a family steeped in UNC traditions dating to the 1800s. When he graduated from Terry Sanford High School, only one college was on his application list — Carolina, where he earned a Bachelor of Science degree with honors in 1986. Attending a world-class research university—where research and teaching are done by the same people—allowed him to work in chemistry labs with top faculty and inspired him to become a professor. He pursued that dream at the California Institute of Technology, where he earned a doctorate in chemistry in 1989, and at Yale University for postgraduate work. After teaching a year at NC State, he returned in 1993 to UNC, where he was dean of the College of Arts and Sciences and chair of the chemistry department before becoming chancellor in 2008. Dr. Thorp is a member of President Obama’s National Advisory Council on Innovation and Entrepreneurship. As a result, the University hosted the council’s first national forum in Chapel Hill. He coauthored “Engines of Innovation— The Entrepreneurial University in the 21st Century,” a UNC Press book that makes the case for the pivotal role of research universities as agents

OCR for page 67
81 APPENDIX C of societal change. Royalties support innovation at UNC. Dr. Thorp serves on the U.S. Manufacturing Competitiveness Initiative for the Council on Competitiveness. He has published 130 scholarly articles on the electronic properties of DNA and RNA and cofounded Viamet Pharmaceutials in Morrisville, which is developing drugs for fungal infections and prostate cancer. The chancellor also is a member of a national Commission on Higher Education Attainment, which was created by the six presidentially based higher education associations to chart a course for greatly improv- ing college retention and attainment and, in turn, restore the nation’s higher education preeminence. Dr. Jake Yeston joined the staff at Science in 2004, where he is now a senior editor, handling peer review for original research manuscripts submitted in chemistry and overlapping segments of applied physics and biochemistry. He earned an AB in chemistry from Harvard University in 1996 and a PhD in chemistry from the University of California-Berkeley in 2001, working jointly under Bob Bergman and Brad Moore on flash kinetics studies of transition metal carbonyl reactions, followed by post - doctoral research in ultrafast infrared spectroscopy at the Max Planck Institute for Quantum Optics (Garching, Germany) and the National Insti- tute of Standards and Technology (Gaithersburg, MD).

OCR for page 67